Cancer patient on a chip

芯片上的癌症患者

基本信息

批准号：
10646186
负责人：
Gordana Vunjak-Novakovic
金额：
$ 51.16万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-15 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10646186
关键词：
3-Dimensional Advanced Malignant Neoplasm Algorithms Architecture Biological Biomedical Engineering Biopsy Bioreactors Blood Blood Vessels Bone Tissue Breast Adenocarcinoma Breast Carcinoma CLIA certified Cancer Biology Cancer Patient Cells Circulation Clinical Data Data Engineering Dependence Development Drug Targeting Drug resistance Endothelial Cells Engineering Extravasation Functional disorder Genetic Transcription Goals Heart Heterogeneity Homing Hormones Human Human Pathology Image Immune Individual Institutional Review Boards Label Link Liver Lung Malignant Neoplasms Mammary Gland Parenchyma Mammary Neoplasms Metastatic Neoplasm to the Lung Metastatic breast cancer Methodology Methods Modality Modeling Neoplasm Circulating Cells Neoplasm Metastasis Normal tissue morphology Oncology Operative Surgical Procedures Organoids Pathology Patients Perfusion Pharmaceutical Preparations Physiological Primary Neoplasm Property Proteins Protocols documentation Publishing Resistance Role Site Slice Specificity Specimen System Systems Biology Testing Therapeutic Thick Tissue Model Tissues Validation Vascular Endothelium Vascularization Woman Work anticancer research bone cancer cell cohort design drug sensitivity drug testing exome human model in vitro Model induced pluripotent stem cell insight malignant breast neoplasm migration neoplastic cell novel novel therapeutics pre-clinical preclinical study predictive modeling predictive panel recruit response scaffold single cell analysis single-cell RNA sequencing therapeutic target transcriptome sequencing triple-negative invasive breast carcinoma tumor tumor progression

项目摘要

SUMMARY The availability of predictive in vitro models of human tumors designed to accurately recapitulate key aspects of human pathophysiology would be transformative to cancer research and pre-clinical validation of new therapeutic modalities. We assembled an interdisciplinary team of leading experts in bioengineering, cancer biology, systems biology, pathology and oncology to establish such model. Based on extensive prior work, we propose to develop a state-of-the art “cancer patient on a chip” of invasive human breast carcinoma. The tumor will be physiologically integrated with their cognate metastatic sites (lung, liver, bone) via vascular perfusion containing circulating cells. The tumor compartment will be established directly from surgical specimens grown in 3D, organotypic conditions while target metastatic sites and vasculature will be established from blood-derived, patient-matched iPS cells, under an active institutional review board protocol. The system is imaging compatible and supports long-term culture (up to 12 weeks). Biological fidelity and heterogeneity of primary and metastatic sites, as implemented in the context of such vascularized multi-tissue platform, will be validated by single-cell analyses vs. the corresponding native tumor. For these studies, we will recruit a cohort of patients with metastatic tumors. Our ultimate goal is to demonstrate utility of the platform in elucidating mechanisms of tumor progression and drug resistance, by testing drug panels predicted by a novel RNA-seq-based, NY CLIA certified methodology (OncoTreat). Our hypothesis is that our system will recapitulate key properties of the metastatic breast adenocarcinoma and enable identification of target proteins that mechanistically drive tumor progression and drug sensitivity/resistance. Three specific aims will be pursued in a highly integrated fashion: Aim 1: Bioengineer a 3D human breast carcinoma model and metastasis host tissues; Establish a model of metastasis in an integrated patient-on-a-chip platform; Aim 3: Elucidate master regulators and predict drug sensitivity in metastatic cells using the “cancer patient on a chip” model. We anticipate that this platform would have broad utility in cancer research and in patient-specific testing of new therapeutic modalities.

概括旨在准确概括钥匙的人类肿瘤的预测性体外模型的可用性人类病理生理学的各个方面将转化为癌症研究和临床前验证新的治疗方式。我们组建了一个由生物工程领先专家的跨学科团队，癌症生物学，系统生物学，病理学和肿瘤学以建立这种模型。基于广泛先前的工作，我们建议开发出最先进的“在侵入性人类乳房的癌症患者” 癌。该肿瘤将与它们的同源转移部位（肺，肝，，骨）通过含有循环细胞的血管灌注。肿瘤室将直接建立从3D生长的手术标本，靶向转移部位和脉管系统将在活跃的机构审查委员会下从血液来源的，患者匹配的IPS细胞中建立协议。该系统成像兼容并支持长期培养（长达12周）。生物原始和转移性站点的保真度和异质性，如在这种情况下实施血管化的多组织平台将通过单细胞分析与相应的本机验证瘤。对于这些研究，我们将招募一组转移性肿瘤患者。我们的最终目标是通过测试由新型基于RNA-SEQ的NY CLIA认证方法（Oncotreat）预测的药物面板。我们的假设是我们的系统将概括转移性乳腺癌和能够鉴定机械驱动肿瘤进展和药物的靶蛋白灵敏度/阻力。将以高度整合的方式追求三个具体目标：目标1：生物工程师 3D人类乳腺癌模型和转移宿主组织；建立一个转移模型集成的片片平台；目标3：阐明主调节器并预测药物敏感性使用“芯片上的癌症患者”模型的转移细胞。我们预计这个平台将有在癌症研究和新治疗方式的患者特异性测试方面的广泛效用。